Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by Indomitableon Aug 11, 2016 9:44am
81 Views
Post# 25130205

RE:RE:One final last thing...

RE:RE:One final last thing...
QUANTUMJUMP wrote: Shiseido having a large % of the revamped structure is incredibly significant 
Where are you getting your information from buddy? You have me at a complete loss at trying to understand how you  think Shieseido is going to get even one share of Replicel's let alone all these other millions you keep talking about.

Show us some facts from somwhere other than your imagination please.

The only fact shown to the public so far in relation to Shiseido and Replicel, money wise is that Shiseido still owes Replicel 30 million U.S. in milestone payments plus royalties. Nothing more is mentioned money wise, share wise or control wise.

I need to see some facts like I said. Until then all it is, is speculation, or wishful thinking to me.
Indomitable Cool

Bullboard Posts